Company intelligence / Profile preview

OXGENE

Oxford, England, United Kingdomoxgene.com ↗

Ownership: Private
Development stage: Commercial

Overview

OXGENE does not have its own clinical results as it provides enabling technologies and contract R&D/manufacturing services to the cell and gene therapy industry. Its proprietary TESSA™ AAV production system and XLenti™ stable producer lines are designed to improve scalability, reduce costs, and simplify viral vector manufacture for partners developing advanced therapies. The company’s innovations support the development of multiple client programs globally.[1][6][7]

Therapeutic areas: Other
Modalities: Gene therapyCell therapyViral vector-based therapies (AAV, lentiviral vectors)Biologic (platforms for biologics manufacturing)
Industry: Contract Manufacturing Organization

Partnerships

WuXi Advanced Therapies/WuXi AppTec (parent)numerous undisclosed partnerships with global biotech/pharma companies as a CRO/CDMO provider.

Beyond the preview

Go deeper on OXGENE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXGENE.

Explore the full profile